Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877380 | 0.89 | SCN9A (0.34) | SCN9ASLC8A1BRD4CREBBPKCNH2 | |
| SCHEMBL4866924 | 0.89 | KCNH2 (0.34) | SCN9ASLC8A1KCNH2HRH3 | |
| SCHEMBL4877344 | 0.88 | SCN9A (0.37) | SCN9ASLC8A1BRD4CREBBPGRIN2B | |
| SCHEMBL4877372 | 0.87 | KCNH2 (0.37) | BRD4CREBBPKCNH2HRH3GRIN2B | |
| SCHEMBL4872000 | 0.87 | GRIN2B (0.38) | BRD4CREBBPKCNH2HRH3GRIN2B | |
| SCHEMBL4877178 | 0.87 | GRIN2B (0.38) | BRD4CREBBPKCNH2HRH3GRIN2B | |
| SCHEMBL4874848 | 0.86 | ALDH1A1 (0.37) | SCN9ASLC8A1 | |
| SCHEMBL4874128 | 0.82 | SLC8A1 (0.33) | SCN9ASLC8A1BRD4CREBBPKCNH2 | |
| SCHEMBL4866852 | 0.81 | KCNH2 (0.37) | KCNH2HRH3 | |
| SCHEMBL2982868 | 0.81 | SLC8A1 (0.36) | SLC8A1BRD4CREBBPGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | SCN9A 2977/4885SLC8A1 3881/4885BRD4 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.